Final analysis of the observational GioTag study: Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small cell lung cancer

Real-world retrospective, observational study reported that across the 203 patients included in the analysis, sequential treatment of afatinib followed by osimertinib provided a median overall survival of 37.6 months and median time to treatment failure of 27.7 months.


Biospace Inc.